English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Chronic obstructive pulmonary disease (COPD) is a very common disease. The global prevalence of COPD has been estimated to approximately 9–10% in populations aged 40 years or more [1]. Because of the development of severe hypoxemia, pulmonary arterial hypertension (PAH) develops late in the course of natural history of patients with COPD. The rate of PAH progression in COPD patients is slow (an increase of <1 mmHg per year) [2], however, the presence of PAH implies a poor prognosis in patients with COPD [3]. As it is known to us all, right heart catheterization (RHC) examination is the golden standard for the diagnosis of PAH, yet it is not practical to be used as a screening test. In the last few years, some researches have supplied with the fact that insulin, high density lipoprotein cholesterol, and C-reactive protein are all correlated with the severity of the patients with PAH [4,5,6]. In our previous study, we also found that circulating plasma ghrelin and obestatin levels were low in COPD patients with PAH [7].These circulating plasma markers could be used to value the severity of PAH and supply us with new pathways or therapeutic targets of PAH. NT-proBNP is a pro-hormone, secreted by the myocardium in response to various stimuli, including mechanical stretch and hypoxia, along with some neurohormonal factors such as catecholamines and Abstract: N-terminal pro-brain natriuretic peptide (NT-proBNP) is a pro-hormone, secreted by the myocardium in response to various stimuli, was found to be correlated with some hemodynamic parameters in pulmonary arterial hypertension (PAH). We investigated plasma NT-proBNP levels and the relationships between NT-proBNP and some hemodynamic parameters in chronic obstructive pulmonary disease (COPD) patients with or without PAH. We found that plasma NT-proBNP level was significantly lower in PAH group compared with the control group (4982.5 ± 22.5 pg/ml vs 5067.5 ± 21.8 pg/ml, P < 0.05). In the study population, only fasting insulin level was found to be positively correlated with fasting NT-proBNP level and only fasting insulin was an independent predictor of NT-proBNP (standardized coefficient = 0.708, P < 0.001) in a multiple regression model analysis. In the PAH group, only fasting insulin was found to be positively correlated with NT-proBNP, whereas other parameters were not found to be correlated with NT-proBNP. Our data suggests that the expression of NT-proBNP might be different in different kinds of pulmonary hypertension.

Plasma N-Terminal Pro-Brain Natriuretic Peptide Level was Lower in COPD Patients with Pulmonary Artery Hypertension